



Influence of backward bifurcation in HBV or HCV infection.

Jane Heffernan
York University
Work with Redouane Qesmi and
Jianhong Wu










Mathematical Modelling of Infectious Diseases



- Epidemiology
 - Spread of disease in a population
- Immunology
 - Spread of an infection in a host

HIV Measles

Hepatitis B, C

Influenza Herpes





Hepatitis

- Hepatitis refers to inflammation of the liver
- Can be caused by alcohol, certain medications and chemical, or by viral infection
- Hepatitis B virus and Hepatitis C virus are two such pathogens




Normal Liver, Fatty Liver, and Cirrhosis

Hepatitis B Virus

- DNA virus that infects liver cells and leads to acute or chronic infection.
- Acute disease for approx 1 year
 - Experience severe symptoms for up to a year, including jaundice, extreme fatigue, nausea, vomiting and abdominal pain.
- Chronic infection leads to cirrhosis or hepatocellular carcinoma.
 - About 25% of chronic carriers die from liver cancer induced by the virus.
 - n 350 million of chronic HBV infections worldwide 5


Hepatitis B Virus



Hepatitis C Virus

- n RNA virus that infects liver cells and leads to acute or chronic infection.
- Acute disease for approx 6 months
 - May experience symptoms including decreased appetite, fatique, abdominal pain, jaundice, itching and flu-like symptoms.
- Chronic infection leads to cirrhosis or hepatocellular carcinoma.
 - One third of chronic carriers develop cirrhosis of the liver.
 - 170 million of chronic HCV infections worldwide,

Hepatitis C Virus



Treatment

- Drug therapy
 - HCV Peginterferon ACRibavirin
 - HBV lamivudine and entecavir
 - Ineffective in eliminating the virus
- Liver transplantation
 - Thought that this would cure patients since liver is primary source of infection
 - New liver is reinfected
 - Rapidly progressing

Standard of care

- The current standard of care (SOC) for HCV involves 48–72 weeks of treatment with pegylated interferon and ribavirin.
- Approximately 40–60% of the patients treated with SOC achieve a sustained viral response (SVR) after this treatment.

Compartments of infection

- The fact that reinfection of the liver after transplantation occurs, suggests that virus is present in other reservoirs
- The virus can be circulating in the blood which ultimately reinfects the liver if drug therapies cannot clear it
- We build on the basic model of in-host dynamics to include a second compartment of infection

Basic Model

$$\frac{dx}{dt} = \lambda - d_x x - \beta x v$$

$$\frac{dy}{dt} = \beta x v - d_y y$$

$$\frac{dv}{dt} = ky - d_v v$$


- x uninfected cells
- n y infected cells
- n v free virus

- λ, k production rate
- β efficacy of infection
- d_x, d_y, d_v death rates/ clearance time

In-host Model

Basic reproductive ratio


The number of secondary infections produced by an initial infective in a totally susceptible population



Basic Model

- Model doesn't show persistence of virus after transplantation, but virus does persist
- We add another compartment of infection
 - n Blood
 - Peripheral blood mononuclear cells and various organs likely contribute to the high rate of re-infection

n Model



Liver-blood-virus model

$$\frac{dx}{dt} = \lambda_x - \beta_x x v - d_x x$$

$$\frac{dy}{dt} = \beta_x x v - a_y y$$

$$\frac{dv}{dt} = k_x y + k_z w - uv - \beta_x x v - \beta_z z v$$

$$\frac{dz}{dt} = \lambda_z - \beta_z z v - d_z z$$

$$\frac{dw}{dt} = \beta_z z v - a_w w$$

$$R_0 = \frac{k_x}{a_y} \frac{\beta_x \overline{x}_0}{\beta_x \overline{x}_0 + \beta_z \overline{z}_0 + u} + \frac{k_z}{a_w} \frac{\beta_z \overline{z}_0}{\beta_x \overline{x}_0 + \beta_z \overline{z}_0 + u}$$

Find disease-free and endemic equilibriaStability does not only depend on R0

- Liver-blood-virus model
 - Uninfected and infected equilibrium

$$\begin{array}{cccc}
x & \frac{\lambda_{x}}{d_{x}} & \frac{\lambda_{x}}{\beta_{x}\overline{v} + d_{x}} \\
y & 0 & \frac{\beta_{x}\lambda_{x}\overline{v}}{(\beta_{x}\overline{v} + d_{x})a_{y}} \\
v & 0 & \overline{v} \\
z & \frac{\lambda_{z}}{d_{z}} & \frac{\lambda_{z}}{\beta_{z}\overline{v} + d_{z}} \\
w & 0 & \frac{\beta_{z}\lambda_{z}\overline{v}}{(\beta_{z}\overline{v} + d_{z})a_{w}}
\end{array}$$

Infected equilibrium

$$A\overline{v}^2 + B\overline{v} + C = 0$$
$$A = u\beta_x\beta_z$$


$$B = ud_z\beta_x + ud_x\beta_z + \lambda_x\beta_x\beta_z \left(1 - \frac{k_x}{a_y}\right) + \lambda_z\beta_x\beta_z \left(1 - \frac{k_z}{a_w}\right)$$

$$C = ud_xd_z + \lambda_x\beta_xd_z\left(1 - \frac{k_x}{a_y}\right) + \lambda_z\beta_zd_x\left(1 - \frac{k_z}{a_w}\right)$$

C<0 is equivalent to R0>1


- n Theorem
 - A unique endemic equilibrium if C<0 (R0>1)
 - A unique endemic equilibrium if B<0 and C=0 or B²-4AC=0
 - Two endemic equilibria if C>0, B<0 and B²-4AC>0
 - No endemic equilibrium otherwise

Transcritical bifurcation $(k_z - a_w)(k_x - a_y) > 0$



Backward bifurcation

$$(k_z - a_w)(k_x - a_y) < 0$$



- Change model assumptions to closer reflect the biology of the system
- n k(a)
 - The proliferation rate of the virus depends on the age of infection, starts low and ramps up to a maximum production rate
- - The mortality rate of an infected cell depends on its age

$$\frac{dx}{dt} = \lambda_x - \beta_x x v - d_x x$$

$$\frac{dy}{dt} + \frac{dy}{da} = -\delta_y(a) y(a,t)$$

$$\frac{dv}{dt} = \int_0^\infty k_y(a) y(a,t) da + \int_0^\infty k_w(a) w(a,t) da - uv - \beta_x x v - \beta_z z v$$

$$\frac{dz}{dt} = \lambda_z - \beta_z z v - d_z z$$


$$\frac{dw}{dt} + \frac{dw}{da} = -\delta_w(a) w(a,t)$$

$$y(0,t) = \beta_x x(t) v(t) \quad w(0,t) = \beta_z z(t) v(t)$$

$$y(a,0) = 0 \quad w(a,0) = 0$$


Production rate

$$k(a) = k_{\text{max}} (1 - e^{-\theta(a - a_1)}), \quad a \ge a_1 \text{ and } 0 \text{ else}$$



Death rate

$$\delta(a) = \delta_0 \text{ if } a < a_2 \text{ and } \delta_0 + \delta_m (1 - e^{-\gamma(a - a_2)}) \text{ if } a \ge a_2$$



$$R_0 = N_y \frac{\beta_x \overline{x}}{\beta_x \overline{x} + \beta_z \overline{z} + u} + N_w \frac{\beta_z \overline{z}}{\beta_x \overline{x} + \beta_z \overline{z} + u}$$

n where
$$N_{y} = \int_{0}^{\infty} k_{y}(a)e^{-\int_{0}^{a} \delta_{y}(s)ds} da$$

$$N_{w} = \int_{0}^{\infty} k_{w}(a)e^{-\int_{0}^{a} \delta_{w}(s)ds} da$$

$$\frac{dx}{dt} = \lambda_x - \beta_x xv - d_x x$$

$$\frac{dz}{dt} = \lambda_z - \beta_z zv - d_z z$$

$$\frac{dv}{dt} = \beta_x \int_0^\infty k_y(a)\sigma_y(a)v(t-a)x(t-a)da + \beta_z \int_0^\infty k_w(a)\sigma_w(a)v(t-a)z(t-a)da$$

$$-uv - \beta_x xv - \beta_z zv$$

$$\sigma_y(a) = e^{-\int_0^z \delta_y(s)ds}$$

$$\sigma_{y}(a) = e^{-\int_{0}^{a} \delta_{y}(s) ds}$$

$$\sigma_w(a) = e^{-\int_0^a \delta_w(s)ds}$$


- If R0 < 1 then the DFE is locally asymptotically stable
- If R0 > 1 then the DFE is unstable
- If $R0 \le 1$ and (Ny 1) $(Nw 1) \ge 0$ then the DFE of the system is GAS.

$$R_0 = N_y \frac{\beta_x \overline{x}}{\beta_x \overline{x} + \beta_z \overline{z} + u} + N_w \frac{\beta_z \overline{z}}{\beta_x \overline{x} + \beta_z \overline{z} + u}$$

Transcritical bifurcation

- $_{n}$ $(Ny 1) (Nw 1) <math>\geq 0$
- The endemic state undergoes a Transcritical bifurcation:
 - For R0 > 1, R0 close to 1, the EE is LAS and the DFE is unstable.
 - The HBV disease persists
 - **n** For R0 ≤ 1, the DFE is GAS.
 - n The HBV disease dies out


Transcritical bifurcation



Backward bifurcation

- $_{n}$ (Ny 1) (Nw 1) < 0
- When R0 = 1, the LVB system undergoes a backward bifurcation
 - For Rc < R0 < 1, there is an endemic equilibrium which is LAS;</p>
 - n The DFE is LAS for R0 ≤ 1;
 - For R0 > 1, the DFE is unstable and an endemic equilibrium appears and is stable.

Backward bifurcation



Conclusions and Future Work

Drug therapy may be effective at reducing Nx < 1 in the liver, but may not be successful in reducing Nz < 1 and therefore, the virus can not be eradicated.</p>

CURRENT DEBATE

- Are there virus producing cells in the blood?!!!!!!
- Can use our model for liver transplantation studies
 - Compare to reate of reinfection data of the new liver
 - Give us an idea if virus and/or infected cells are needed for this to occur

Acknowledgements

- n Dr. Redouane Qesmi (York)
- Dr. Jianhong Wu (York, CDM)
- n Dr. Jun Wu (PHAC)
- Dr. Susie ElSaadany (PHAC)
- n NSERC
- n MITACS
- n ERA


- n Group:
- Undergrads:


Alexandra Teslya, Naamah Jacobs, Ramnath Bagavath, Amir Razavi

- **Grad**
 - Shannon Collinson, Yimin Du, Yan Wang, Navjot Singh, Roman Khaykin
- Post Doc
 - Suma Ghosh, Redouane Qesmi, Venkata Duvuurri, Qian Wang, Vahid Anvari
- n Collaborators

Neal Madras, Jianhong Wu, Robert Smith? 35


Immune System





- Innate immunity
- Adaptive immunity
 - Humoral and cell mediated


Immune System



- Macrophages,Dendritic cells, etc
- Lymphocytes
 - T − produced by thymus
 - n CD4
 - Helper T-cells
 - Activated by antigen presenting cells
 - Activate the rest of the immune response
 - CD8
 - Killer T-cells
 - B produced in bone marrow
 - Mature in spleen
 - Plasma cells, antibodies
 - Naive, activated memory

Immune System

- Macrophages, Dendritic cells, etc
- Lymphocytes
 - T − produced by thymus
 - n CD4
 - Helper T-cells
 - Activated by antigen presenting cells
 - Activate the rest of the immune response
 - n CD8
 - Killer T-cells
 - B produced in bone marrow
 - Mature in spleen
 - Plasma cells, antibodies
 - Naive, activated memory



Basic Model

